Skip to main content
OpenTrials
Completed

NCT Number: NCT00206752

Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck

The purpose of this study is to assess the feasibility of avoiding opposite side neck radiation therapy in patients with clearly one side squamous cell cancer of the head and neck. We aim to assess the reduction in treatment volume (amount of radiation therapy required), and the resultant xerostomia and mucositis, with the delivery of unilateral neck radiation therapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beth Israel Medical Center

New York, 10003, United States

About this study

Patients will be treated with definitive external beam radiation plus/minus chemotherapy plus/minus neck dissection in the ipsilateral neck (post radiation). The primary site will be treated with definitive radiation therapy, or definitive surgery plus post-operative radiation therapy. Primary endpoints are loco-regional control, as well as quality of life, xerostomia, mucositis, and neck fibrosis.

Salivary evaluations shall be performed prior to the initiation of radiation therapy, during the second week of EBRT, and at the completion of radiation. Evaluations will also be conducted at 3, 6, and 12 months after the completion of EBRT.

Oral mucositis will be assessed prior to the initiation of EBRT and weekly during EBRT. Evaluations will also be conducted at 3 and 6 months after the completion of EBRT. Two standardized mucositis scales will be used: the RTOG scale and the WHO scale.

Clinical response will be evaluated by physical exam and PET/CT. PET/CT scans will be done at 3, 6, 12, 18, and 24 months, and then when clinically indicated during follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Squamous cell carcinoma of the oral cavity or oropharynx, with the primary lesion >1 cm from the midline.
  • Patient has no clinical or radiologic evidence of contralateral neck node metastases.
  • No evidence of distant metastasis.
  • No previous history of radiation therapy or chemotherapy
  • performance status 0-2
  • Age >= 18
  • Signed informed consent
  • Patients must be accessible for treatment and follow-up

Exclusion criteria

  • HIV positive patients
  • Pregnancy or any patients not practicing contraception
  • Active tobacco or alcohol addiction (as assessed by medical caregiver)
  • Serious comorbid disease which prevents delivery of full treatment including psychiatric disorders, cardiopulmonary disease, etc.
  • Concomitant use of any trial anticancer therapeutic within 30 days of entry
  • Uncontrolled hypertension
  • Known hypersensitivity to mammalian cell-derived products

Treatment and study plan

radiation therapy

Radiation

definitive external beam radiation in the ipsilateral neck.

definitive external beam radiation in the ipsilateral neck

Radiation

definitive external beam radiation in the ipsilateral neck

Primary outcomes

  1. FACT (head and neck);Xerostomia related Quality of Life Questionnaire

    Time frame: September 2010

Sponsors and collaborators

Lead sponsor

Beth Israel Medical Center

Other

Registry information

Official study title

A Randomized Prospective Evaluation of Unilateral/Ipsilateral Neck Irradiation in Selected Patients With Squamous Cell Carcinoma of the Head and Neck Who Are Managed by Radiation Therapy

Acronym: Unilateral

Important dates

Study start
2004
Primary completion
2015
Study completion
2015
First posted
Sep 21, 2005
Registry last updated
Mar 30, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.